Communications Biology (Jul 2023)

Crosstalk between KIF1C and PRKAR1A in left atrial myxoma

  • Mengchen Zhou,
  • Yan Yao,
  • Xiangyi Wang,
  • Lingfeng Zha,
  • Yilin Chen,
  • Yanze Li,
  • Mengru Wang,
  • Chenguang Yu,
  • Yingchao Zhou,
  • Qianqian Li,
  • Zhubing Cao,
  • Jianfei Wu,
  • Shumei Shi,
  • Dan Jiang,
  • Deyong Long,
  • Jiangang Wang,
  • Qing Wang,
  • Xiang Cheng,
  • Yuhua Liao,
  • Xin Tu

DOI
https://doi.org/10.1038/s42003-023-05094-5
Journal volume & issue
Vol. 6, no. 1
pp. 1 – 12

Abstract

Read online

Abstract Cardiac myxoma (CM) is the most common benign cardiac tumor, and most CMs are left atrial myxomas (LAMs). Six variations of KIF1C, c.899 A > T, c.772 T > G, c.352 A > T, c.2895 C > T, c.3049 G > A, and c.*442_*443dup in left atrial myxoma tissues are identified by whole-exome sequencing (WES) and Sanger sequencing. RNA-seq and function experiments show the reduction of the expression of KIF1C and PRKAR1A caused by rare variations of KIF1C. KIF1C is observed to be located in the nucleus, bind to the promoter region of PRKAR1A, and regulate its transcription. Reduction of KIF1C decreases PRKAR1A expression and activates the PKA, which causes an increase in ERK1/2 phosphorylation and SRC-mediated STAT3 activation, a reduction of CDH1, TP53, CDKN1A, and BAX, and eventually promotes tumor formation both in vitro and in vivo. The results suggest that inhibition of KIF1C promotes the pathogenesis of LAM through positive feedback formed by the crosstalk between KIF1C and PRKAR1A.